Humedix Co., Ltd. (200670.KQ)
KRW 42800.0
(3.38%)
KRW 42800.0
(3.38%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 54.87 Billion KRW | 31.7% |
| 2022 | 48.99 Billion KRW | 32.76% |
| 2021 | 31.13 Billion KRW | 2.48% |
| 2020 | 30.61 Billion KRW | 23.56% |
| 2019 | 22.15 Billion KRW | 22.56% |
| 2018 | 19.06 Billion KRW | 11.0% |
| 2017 | 20.81 Billion KRW | 6.37% |
| 2016 | 14.71 Billion KRW | 96830.73% |
| 2015 | 16.5 Billion KRW | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 13.35 Billion KRW | 42.59% |
| 2024 Q2 | 15.95 Billion KRW | 35.58% |
| 2023 Q1 | 12.14 Billion KRW | 31.18% |
| 2023 Q4 | 7.91 Billion KRW | -43.81% |
| 2023 FY | - KRW | 31.7% |
| 2023 Q3 | 14.09 Billion KRW | -0.33% |
| 2023 Q2 | 14.14 Billion KRW | 16.44% |
| 2022 Q1 | 7.12 Billion KRW | -8.13% |
| 2022 Q4 | 9.25 Billion KRW | -11.38% |
| 2022 FY | - KRW | 32.76% |
| 2022 Q3 | 10.44 Billion KRW | 1.77% |
| 2022 Q2 | 10.26 Billion KRW | 44.05% |
| 2021 Q3 | 6.03 Billion KRW | -5.81% |
| 2021 Q1 | 7.52 Million KRW | -25.12% |
| 2021 Q2 | 6.4 Billion KRW | 85061.12% |
| 2021 Q4 | 7.75 Billion KRW | 28.54% |
| 2021 FY | - KRW | 2.48% |
| 2020 Q1 | 4.91 Million KRW | -24.2% |
| 2020 FY | - KRW | 23.56% |
| 2020 Q4 | 10.04 Million KRW | 54.55% |
| 2020 Q3 | 6.5 Million KRW | 15.36% |
| 2020 Q2 | 5.63 Million KRW | 14.67% |
| 2019 Q3 | 5.77 Million KRW | 11.05% |
| 2019 Q2 | 5.19 Million KRW | 10.5% |
| 2019 Q1 | 4.7 Million KRW | -11.87% |
| 2019 FY | - KRW | 22.56% |
| 2019 Q4 | 6.48 Million KRW | 12.31% |
| 2018 Q4 | 5.33 Million KRW | 2.23% |
| 2018 FY | - KRW | 11.0% |
| 2018 Q1 | 3.96 Million KRW | -0.03% |
| 2018 Q2 | 3.27 Million KRW | -17.21% |
| 2018 Q3 | 5.22 Million KRW | 59.19% |
| 2017 Q2 | 3.8 Million KRW | 8.64% |
| 2017 FY | - KRW | 6.37% |
| 2017 Q1 | 3.5 Million KRW | -17.01% |
| 2017 Q4 | 3.96 Million KRW | -25.21% |
| 2017 Q3 | 5.29 Million KRW | 39.26% |
| 2016 Q2 | 3.78 Million KRW | -2.55% |
| 2016 Q1 | 3.88 Million KRW | 0.0% |
| 2016 FY | - KRW | 96830.73% |
| 2016 Q3 | 3.18 Million KRW | -16.0% |
| 2016 Q4 | 4.21 Million KRW | 32.63% |
| 2015 FY | - KRW | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| HLB Pharmaceutical Co., Ltd | 581.09 Million KRW | -9343.357% |
| CMG Pharmaceutical Co., Ltd. | 5.59 Billion KRW | -880.863% |
| Celltrion Pharm, Inc. | 54.22 Billion KRW | -1.2% |
| Huons Global Co., Ltd. | 151.92 Billion KRW | 63.881% |
| DongKook Pharmaceutical Co., Ltd. | 88.68 Billion KRW | 38.125% |
| Enzychem Lifesciences Corporation | -5.77 Billion KRW | 1050.42% |
| Boditech Med Inc. | 36.48 Billion KRW | -50.388% |
| EuBiologics Co., Ltd. | -4.39 Billion KRW | 1349.469% |
| FutureChem Co.,Ltd | -591.25 Million KRW | 9380.99% |
| Huons Co., Ltd. | 74.23 Billion KRW | 26.078% |
| BNC Korea Co., Ltd. | 14.17 Billion KRW | -287.217% |
| AptaBio Therapeutics Inc. | -13 Billion KRW | 521.962% |